This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Middle/ External Ear Disorders  • Randomized Controlled Trial  • Alert me on articles by topic  Social Bookmarking   What's this?

Impact on Otitis Media and Otolaryngology

Charles D. Bluestone, MD
From the Department of Pediatric Otolaryngology, University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh, Pittsburgh, Pa.

Corresponding author and reprints: Charles D. Bluestone, MD, Department of Pediatric Otolaryngology, Children's Hospital of Pittsburgh, 3705 Fifth Ave at DeSoto Street, Pittsburgh, PA 15213.

Arch Otolaryngol Head Neck Surg. 2001;127:464-467.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In February 2000, the new 7-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV7) (Prevnar; Wyeth Lederle Vaccines, Pearl River, NY) was approved by the Food and Drug Administration (FDA) for the prevention of invasive pneumococcal disease (eg, meningitis and bacteremia) in infants and young children. This long-awaited event has received widespread applause from pediatric infectious disease experts who anticipate a dramatic decrease in these potentially fatal serious infections as the infants and young children who are at high risk become immunized.^{1, 2} The Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP) recommends that the vaccine be given to all infants aged 2 to 23 months and to children aged 24 to 59 months who are at increased risk for pneumococcal disease, such as those who have sickle cell disease, human immunodeficiency disease virus infection, and other immunocompromising or chronic medical conditions.³ The ACIP also recommends . . . [Full Text of this Article]

OUTCOMES OF THE CLINICAL TRIALS


ANTICIPATED IMPACT OF CONJUGATE VACCINE ON AOM AND ITS SUPPURATIVE COMPLICATIONS

ROLE OF THE OTOLARYNGOLOGIST

CONCLUSIONS


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prevention of Meningitis: Cochlear Implants and Inner Ear Abnormalities
Bluestone
Arch Otolaryngol Head Neck Surg 2003;129:279-281.
FULL TEXT